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Background Global statistics of cancer diseases reported that gastric cancer is ranked the 5 th common cancer and the 3 rd common cause of deaths among patients with cancers [1] . This condition is predominant in males, with males to females ratio of 2:1 and the onset of the disease is commonly above 60 years [2] . For malignancies detected in early stages, a surgical procedure is the treatment of choice to cure the disease, but for those patients present with more advanced-stage malignancies, outcomes are poor [3] . The members of the VEGF family are five VEGF glycoproteins (VEGF-A, VEGF-B, VEGF-C, VEGF-D and VEGF-E) and placental growth factors 1, 2. VEGF families bind to vascular endothelial growth factors receptors such as VEGFR1 (Flt-1), VEGFR2 (Flk-1-KDR) and VEGFR3, which are expressed on the lymphatic and vascular endothelium; these are tyrosine kinase receptors. VEGF and its receptor are highly expressed in many malignancy types, including cancer found in the gastrointestinal tract. VEGF expression leads to the development and maintenance of a vascular network that promotes tumor growth and metastases. VEGF (A, B, C and D) are vascular endothelial growth factors families which have been implicated in the prognosis and clinicopathological picture of gastric cancer. VEGF families have been shown to cause neo-vascularisation, lymphangiogenesis, invasion depth of the tumor, metastasis, vascular invasion, and be associated with TNM staging. Studies have shown that metastasis and peritoneal dissemination are results of gastric cancer progression, and were the roleplayed by VEGF-A [4] [5] [6] . Some experimental studies have showed thatlymph node invasion is caused byVEGF-C and VEGF-D by acting as lymphangiogenic factors, enhancing lymphangiogenesis in tumors by binding to their specific receptors on the lymphatic tissues [7] [8] [9] [10] . This review aims to assess the relationship of clinicopathological and prognostic outcomes of patients with gastric cancer, present with overexpression of VEGF families in gastric cancer tissues. 
Methodology

Study inclusion and exclusion criteria
The inclusion criteria mentioned were as follows below.
(1) The studies involving patients with resected gastric tumor (2) After resection, a sample of gastric cancer tissue taken for histopathological examination. 
Data collection and quality assessment
The review and data collection was conducted independently by two investigators (Brian Mawalla and Phillipo L Chalya). The consensus was sought to solve disagreements. The primary data obtained from the literature were first authors, gender, publication year, magnitude of the study, detailed histological classification, positive cases of VEGF, various stages of tumor (TNM), VEGFover expression in sample tissue, overall response rate (ORR), median progression-free survival (PFS), overall survival (OS) and their hazard ratio (HR). Qualities of studies methodology were assessed using Cochrane reviewer's criteria by reviewers BM and PLC independently.
Statistical data analysis
STATA SE v. 13.1 (STATA_ Corporation, Texas, USA) has been used to analyze data. Logistic regression and chi-square tests was used to identify the correlation between the level of the VEGF families' expression and the clinicopathological parameters. OS and PFS were calculated by using Kaplan-Meier method. Cox proportional hazards regression was used to calculate HR. Statistical significant p-value was taken to be P<0.05, and two sided alpha of 5% implemented to determine confidence intervals and p-values.
Results
Study selection
The primary search made 96 studies available for review, and reviewers chose 58 potential pieces of literature for full-text review. As many as 46 studies were excluded as they were found to have irrelevant information on the outcome of interest, this left 12 eligible studies for further review. Figure 1 shows a selection of the studies in this review.
Patient characteristics
2,089 patients were encompassed in this review. Gastric cancer tissues were taken surgically to detect VEGF strong expression in gastric tissues, and VEGF families' over expression in those tissues were detected by using immunohistochemical technique. 214 was the median number of patients, (ranges from 30 to 340). In this review, VEGF types (families) were studied in relation to prognosis and clinicopathological outcome.
Expression of VGEF families in gastric cancer tissue and its relationship to prognosis and clinicopathological outcomes VEGF-A:
Different studies investigate the VEGF-A detection in gastric tissues taken from patients with gastric cancer, and correlate with prognosis and clinicopathological outcome, one study showed that, the VEGF-A overexpression had unfavorable impact on DFS (HR = 1.85; 95% CI, 1.39-2.32) and (OS (HR = 1.57; 95% CI, 1.30-1.84) in gastric cancer patients; and this conclude that, VEGF-A expression shows a poor outcomes on OS and DFS in gastric cancer patients [11] . A positive significant association was seen between VEGF-A overexpression and TNM stage (P=0.047), and low VE GF-A expression was seen more in tumors with TNM stage I-II group (51.2%) compared to the group with TNM stage III-IV (48.8%), high VEGF-A expression (69.4%) was seen in-group of TNM stage III-IV compare to groupwith TNM stage I-II (30.6%); Furthermore, the VEGF-A strongexpression was observed to associate with the size of the tumor (P=0.028) and expression of VEGF-A was found to increase the risk of positive lymph nodes (P=0.002) and lymphovascular invasion (P=0.001) in gastric cancer patients [12] . Similar studies revealed that, VEGF-A strong expression was significant correlate with vascular invasions, formation of ascites, distant metastasis, haematogenous metastasis and tumor neo-vascularisation [13, 14] .
VEGF-B:
There are limited studies that have been done to demonstrate the relationship between VEGF-B overexpression and clinicopathological outcomes. Research was done to quantify overexpression of VEGF-A and over-expression of VEGF-B, and results showed that VEGF-A tends to overexpress in gastro-esophageal cancers and correlates with tumor invasion, while VEGF-B does not seem to be involved in these tumors [14] .
VEGF-C:
The strongest relationship was revealed among VEGF-C over-expression with lymph node status, the invasion of venous tissues, invasion of lymphatic tissues and tumor-infiltrating patterns [15] . Related studies showed that patients with strong expression of VEGF-C presented with significantly poorer prognosis compared to those presented with low VEGF-C expression, and other similar studies showed poor prognoses in gastric cancer patients who presented with VEGF-C over-expression compared to those with low expression of VEGF-C [16, 17] . A study done, and showed there was no association between depth of gastric cancer invasion, size of gastric 3/5 Discussion 2,089 patients were involved in this systematic review, and 12 eligible literatures were used to assess the clinicopathological and prognostic outcomes of VEGF's families expression in gastric cancer patients. Among known VEGF family, VEGF-A (VEGF) is the most common frequently studied subtype in gastric cancer [31] . Numerous studies have evaluated the importance of VEGF-A over expression as an independent prognostic marker in gastric cancer patients; however, these studies have shown conflicting results [32] [33] [34] [35] . VEGF-A up-expression has been demonstrated in the recent meta-analysis as a poor prognosis factor in patients with gastric cancer regarding OS and DFS [11] . This systematic review used the Kaplan-Meier survival method to analyze the significant prognostic value of VEGF-A in GC. In gastric cancer,patients with high expression levels of VEGF-A showed poor prognosis compared to those with low expression levels of VEGF-A.
Different studies have demonstrated that there is no association between VEGF-B expression and prognosis outcomes; also VEGF-B expression and clinicopathological outcomes in gastric cancer patients [14, 15] . One study, which analyzed the expression of both VEGF-A and VEGF-B showed that only VGEF-A was associated with prognosis and clinicopathological outcomes in patients with gastric carcinomas while no correlation was demonstrated in patients presented with the expression of VEGF-B [14] .
The previous report has demonstrated that lymphatic system invasion (lymphatic tissue and lymph nodes) in gastric cancer was positive correlated with expression VEGF-C [16, 17, 21, 22] . VEGF-C has been reported by Amioka et al. and Yanai et al. [21, 37] as an important molecule in facilitating microvessel density and lymph node metastasis in gastric cancer, VEGF-C expression in GC was also found to associate with invasion of blood vessels [16, 17] .
Over expression of VEGF-D have been reported to have significant tumor, gender, age at time of surgery, tumor location and VEGF-C over-expression; although there was relationship between VEGF-C over-expression, TNM staging, vascular invasion and lymphatic invasion (P<0.01) [18] .
Similar studies showed VEGF-C over-expression on tissue obtained from gastric cancer patients were positively associated with lymphatic system invasion (lymph tissues and lymph nodes invasion) [19] [20] [21] . Also, VEGF-C expression seen in early stage of gastric cancer was positive correlated with lymphatic invasion, and this could be hypothetically helpful to predict the effectiveness of less or more extensive surgical resections and lymph node clearance in patients with gastric cancer [20] . One study showed that gastric carcinoma (GC) exhibit high level of VEGF-C expression which was 54.90% compared to 35.29% in normal gastric tissues. The same study also showed that VEGF-C expression was significantly associated with less survival rates and lymph node metastasis in patients with GC [22] .
VEGF-D:
The study was done to elucidate the expression of VEGF-D in GC and it was found to be statistically significantly associated with lymphatic system invasion (lymphatic tissue and lymph node), depth of tumor invasion and tumor differentiation in early gastric cancer [22] . Also, evaluation of VEGF-D in other studies was found to correlate with the spread of tumor to lymphatic tissues, depth of tumor invasion and poor prognosis in colorectal, endometrial, ovarian, and breast cancer [23] [24] [25] [26] [27] [28] . The presence VEGF-D in gastric tissues presented poor prognosis or unfavorable outcomes compared to the group with absence of VEGF-D expression in patients with gastric cancer, VEGF-D also used as a prognostic marker in patients with GC after surgical resection [22, 29] . A study has shown that, the size of the tumor, distant metastasis and invasion of both lymphatic and venous tissues were significantly correlated with expression of VEGF-D; also VEGF-D can be used to evaluate RFS AND OS in patients with gastric cancer [30] .
A total of 96 studies were identi�ied through literature search 58 studies were screened for full-text articles 12 full-text articles were eligible for this systematic review 38 studies were excluded, as they were uninformative on outcomes of interest 46 studies were excluded as they were abstracts without full-text 
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association with poor prognosis, lymphatic metastases and decreased survival in patients with gastric cancer; however, those patients with absence of VEGF-D expression in their gastric tissues had a favorable prognosis [29] . Meta-analysis was done and suggested that over expression of VEGF-C and VEGF-D in gastric cancer was associated with poor prognosis [36] .
Conclusion
This systematic review demonstrated that overexpression of VEGF proteins, especially VEGF-A, C and D, in gastric cancer is associated with poor prognosis and clinicopathological outcomes and therefore, may be used as a prognostic marker (for prediction of prognosis outcomes) and predictive marker (for evaluation of clinicopathological findings, (e.g., TNM stage, size tumor, invasion to the lymph nodes and invasion to the lymphovascular system) in gastric cancer patients. We recommend that VEGF be a biological marker, and to be measured in all resected gastric cancer tissues for prediction of prognosis and clinicopathological outcomes of gastric cancer patients.
Limitations
The inclusion of only Asian populations in the studies may have excluded some information present in studies in non -Asia population.
(2) Exclusion of studies published in a language other than English may exclude information needed in this review.
